Sarasota, FL -- (SBWIRE) -- 11/03/2017 -- According to the report, the global calcium channel blocker market accounted for USD 11.26 billion in 2016 and is expected to reach USD 15.31 billion, growing at a CAGR of around 5.4% between 2017 and 2022.
Calcium channel blockers (CCBs) or calcium antagonists are among the most widely used drugs in cardiovascular medicine. CCBs promote vasodilator activity and thus act by reducing calcium influx into vascular smooth muscle cells by interfering with voltage-operated calcium channels in the cell membrane. This activity of calcium channel blockers helps for treating Hypertension and various other cardiovascular diseases.
Request Free Sample Research Report @ http://atozresearch.com/chemical-materials/calcium-channel-blocker-market-global-industry-by-2022/
The market of global calcium channel blocker has been accelerated by rising prevalence of hypertension across the globe. Moreover, calcium channel blockers are an essential class of cardiovascular drug prescribed by a physician for the treatment of hypertension which helps in propelling the growth of calcium channel blocker market. Furthermore, its wide application in pharmaceutical industry is expected to fuel the growth of global calcium channel blocker market. As well, the rising percentage of the obese population is also considered as a major driving factor for the growth of CCB market. However, availability of alternatives and certain side effect of CCB can restrict the growth of calcium channel blocker market. Nonetheless, ongoing research and development and combination therapy will serve as major opportunities for upcoming growth of calcium channel blocker market.
Based on product, calcium channel blocker market segmented into two types: Dihydropyridine and Non-Dihydropyridine. Dihydropyridine market is further sub-segmented into Amlodipine, Cilnidipine, Felodipine, Verapamil, Diltiazem, Isradipine, Nicardipine, Nisoldipine, Nifedipine and others. In 2016, amlodipine held the largest market share in terms of total revenue generation in the Dihydropyridine market. This growth is attributed due to the most preference by the physician or consultant towards amlodipine over the other drugs.
Based on application, calcium channel blocker market segmented into five types: hypertension, angina pectoris, pregnancy, anti-obesity and other. Hypertension dominated the calcium channel blockers market in 2016. This segment accounted for the largest market share in term of revenue generation in 2016. The growth of hypertension market is attributed due to large hypertension patient population than any other illness which can be treated by CCB.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global calcium channel blocker include Pfizer Inc., AstraZeneca plc., bayer healthcare llc., GlaxoSmithKline plc., Sanofi S.A., Johnson & Johnson, Abcam, AbMole Bioscience, and Clearsynth.
A to Z Research is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. A to Z Research is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.